Celltrion Pharm Inc (068760) — Cash Flow-to-Debt Ratio
Celltrion Pharm Inc (068760) has a Cash Flow-to-Debt Ratio of 0.07x as of September 2025, meaning its operating cash flow of ₩23.44 Billion could theoretically repay 0% of its total liabilities (₩319.38 Billion) in one year. See 068760 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Celltrion Pharm Inc Cash Flow-to-Debt Ratio (2014–2024)
Historical debt coverage capacity for Celltrion Pharm Inc across 11 annual periods. Also explore Celltrion Pharm Inc (068760) net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Celltrion Pharm Inc (2014–2024)
Year-by-year debt coverage analysis for Celltrion Pharm Inc. For market capitalisation and broader financial context, see Celltrion Pharm Inc (068760) total market value.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.21x | ₩56.59 Billion | ₩272.54 Billion | ▲ +528.3% |
| 2023 | 0.03x | ₩8.76 Billion | ₩264.98 Billion | ▲ +298.4% |
| 2022 | -0.02x | ₩-4.05 Billion | ₩242.94 Billion | ▼ -105.5% |
| 2021 | 0.30x | ₩93.15 Billion | ₩305.92 Billion | ▲ +107.9% |
| 2020 | 0.15x | ₩36.25 Billion | ₩247.51 Billion | ▲ +0.4% |
| 2019 | 0.15x | ₩27.85 Billion | ₩190.95 Billion | ▲ +85.9% |
| 2018 | 0.08x | ₩14.31 Billion | ₩182.41 Billion | ▲ +236.4% |
| 2017 | -0.06x | ₩-10.16 Billion | ₩176.65 Billion | ▲ +37.5% |
| 2016 | -0.09x | ₩-15.21 Billion | ₩165.37 Billion | ▼ -258.7% |
| 2015 | 0.06x | ₩13.36 Billion | ₩230.54 Billion | ▼ -34.2% |
| 2014 | 0.09x | ₩17.33 Billion | ₩196.74 Billion | — |